Pamplona, 18/12/2025 – Elena Erroba, Chief Commercial Officer at 3PBIOVIAN, has renewed her position as a board member of the Spanish Association of Biotech Companies (AseBio) following elections held today in Madrid.
For the past few months, Elena Erroba has represented 3PBIOVIAN on the Board, taking over the role previously held by her CEO, Dámaso Molero. Following today’s election process, Erroba will continue her work with the aim of actively contributing to the development and strengthening of the biotechnology sector in Spain, with a particular focus on bio-manufacturing and industrial capacity.
With over two decades of experience in biotechnology, Elena Erroba has built her career in the development, production, and commercialization of recombinant proteins and advanced therapies. For the past 15 years, she has led the commercial strategy at 3PBIOVIAN, supporting international biotech and pharmaceutical companies in the development and industrial scaling of new therapies.
Her association with AseBio dates back to 2008–2009, when she served as Project Director, gaining firsthand insight into the structural challenges of the sector. Since then, she has maintained a strong commitment to innovation, industrialization, and the development of specialized talent.
Additionally, following today’s elections, Cristina Nadal, Executive Director of Government Affairs at MSD Spain, has been elected President of the Spanish Association of Biocompanies (AseBio), with Rocío Arroyo, CEO of Amadix, as First Vice President; Santiago de Torres, President of Atrys Health, as Second Vice President; and Carlota Gómez de la Hoz, Executive Director of Corporate Affairs and Sustainability at Hipra, as Third Vice President.
Link to AseBio full news: https://www.asebio.com/actualidad/noticias/cristina-nadal-directora-ejecutiva-government-affairs-msd-espana-nueva-presidenta-asebio